Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 05-Oct-2018

Kalos Therapeutics, Inc


Kalos Therapeutics, Inc. is a biomedical company developing a class of therapeutic peptides to fight cancer. These peptides have already shown significant clinical activity in cardiovascular, cancer and veterinary indications. Kalos’ drugs replicate a natural, anti-proliferative activity by disrupting tubulin activity. Our lead drug candidate, KTH-222, is a safe, non-toxic drug which may be used as 1) a front-line therapy, 2) a long-term maintenance therapy or 3) a co-therapy which reduces time to chemoresistance and minimizes chemo side-effects. KTH-222 reduces tumor size while addressing complications, such as metastasis, thereby, allowing the patient to maintain a quality of life not seen with chemotherapy treatments alone. Initial cancer markets include pancreatic, ovarian, prostate, lung and liver. An animal division will develop drugs for the treatment of cancer, retinal and renal disease, congestive heart failure, and epistaxis.


Original YouTube URL: Open

Introduction Video


Additional Questions

Who is your customer?

Specialty Oncologist, teaching hospitals academic centers, and ultimately the patients.

What problem does this idea/product solve or what market need does it serve?

Problems with existing cancer therapies: survival, most therapies have limited survival rates, They are Highly Toxic / or unsafe for long-term usage and most cause the body to build up resistance to chemotherapy and then fail, I/O comes with a new set of side effects and concerns.

What attributes will make this idea/product successful? Why do you believe that those features will create success?

The Kalos Solution is efficacious and can be combined with chemotherapy and immunotherapy, to enhance their effect while lessening side-effects. Our drug can also be used as a long-term maintenance therapy, as it is less toxic, safer and well tolerated which leads to improved quality-of-life for p[atients and their families. Combining our drug with chemo helps reduce the debilitating side-effects of chemo, extends treatment and reduces or eliminates resistance

Explain how you (your team) will execute to make this idea/product successful? What gives you (your team) an advantage over others already in the market or new to this market?

Each team member has been in C-level positions in both Big Pharma and Biomedical Companies, while each is a respected and well recognized as Key Opinion Leaders in cancer. This combination of Big Pharma and Start-up experience has brought perspective to Kalos allowing the company to function seamlessly as a virtual drug development company leveraging external resources of the best and brightest in the Pharmaceutical industry. The team has a track record of pioneering novel new drugs in cancer and other hyperproliferative diseases. The experience and knowledge of drug development in challenging spaces with fatal diseases are far more daunting than most drug development.